27.02.2019: New Data on Cardio-Oncology
This new study will be presented at the upcoming SOT Conference in March:
In this in-vitro study, paclitaxel (Taxol) and the combination of cyclophosphamide, doxorubicin and 5-fluouracil (CAF) were investigated using human iPSC derived cardiomyocytes via impedance recordings on CardioExcyte 96.
Paclitaxel is a microtubule-stabilizing drug that is approved by the FDA for the treatment of ovarian, breast, and lung cancer.
The CAF chemotherapy regimen if often used in the adjuvant setting for the treatment of nonmetastatic breast cancer or alone for the treatment of metastatic breast cancer. However, apart from their benefits in fighting cancer, both treatments induce possible heart damage in the clinic, making cardiac toxicity an important side effect of anticancer therapies.
Here, we monitored the acute and chronic effects of both paclitaxel and CAF on iPSC derived cardiomyocytes.
Weaver BA. How Taxol/paclitaxel kills cancer cells. Mol Biol Cell. 2014;25(18):2677-81.
Florescu M, Cinteza M, Vinereanu D. Chemotherapy-induced Cardiotoxicity. Maedica (Buchar). 2013;8(1):59-67.
Subscribe to our monthly Newsletter, we keep you informed: